Code LY3437943 Verified purity 99.67% HPLC Storage 28 C, dark Read the research, not the marketing 40 study summaries covering mechanisms, published trials and what the literature actually reports cited throughout
People on the maximum dose lost an average of 85 lb after 104 weeks, or slightly more than 30 percent of their starting body weight
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from semaglutide and tirzepatide
The countdown timer The current promotional landing page displays a "Summer Sale" countdown clock (roughly fifteen minutes remaining at the time this page was reviewed) alongside "LAST DAY TO GRAB THIS!" messaging and a 70% discount claim against a stated $99.99 retail price
Research-grade Retatrutide is widely used to probe the comparative pharmacology of mono-, dual-, and tri-agonist incretin systems
Clinical Diabetes : A Publication of the American Diabetes Association, 38 (1), 109-111
